Zobrazeno 1 - 10
of 1 020
pro vyhledávání: '"Se-hoon Lee"'
Autor:
Kyeongmi Lee, Honghui Cha, Jaewon Kim, Yeongjun Jang, Yelin Son, Cheol Yong Joe, Jaesang Kim, Jhingook Kim, Se-Hoon Lee, Sanghyuk Lee
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Immune checkpoint blockades are actively adopted in diverse cancer types including metastatic melanoma and lung cancer. Despite of durable response in 20–30% of patients, we still lack molecular markers that could predict the patient respo
Externí odkaz:
https://doaj.org/article/cadd187922d04c788810db957315fd0e
Autor:
Hyungtai Sim, Hyun Jung Park, Geun-Ho Park, Yeon Jeong Kim, Woong-Yang Park, Se-Hoon Lee, Murim Choi
Publikováno v:
eLife, Vol 13 (2024)
Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have reveale
Externí odkaz:
https://doaj.org/article/e3861aebdafb4a0fb0b8faf2d0801a3d
Autor:
Dae-Ho Choi, MD, Miso Kim, MD, PhD, Young Saing Kim, MD, PhD, Keon Uk Park, MD, PhD, Jang Ho Cho, MD, PhD, Hongsik Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Heejoon Ahn, MD, PhD, Il-Hwan Kim, MD, PhD, Kyung-Hee Lee, MD, PhD, Gyeong-Won Lee, MD, PhD, Seong Yoon Yi, MD, PhD, Beung chul Ahn, MD, PhD, Min-Young Lee, MD, PhD, Hyun Ae Jung, MD, PhD, Sehhoon Park, MD, PhD, Jong-Mu Sun, MD, PhD, Jin Seok Ahn, MD, PhD, Se-Hoon Lee, MD, PhD, Myung-Ju Ahn, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100734- (2024)
Introduction: The role of maintenance durvalumab after definitive concurrent chemoradiotherapy (CCRT) in unresectable locally advanced NSCLC with EGFR mutation or ALK translocation remains unclear. We compared the effectiveness of durvalumab maintena
Externí odkaz:
https://doaj.org/article/5adc6e00d2074509b50a281b9eca7f23
Autor:
Nayoung Kim, Sehhoon Park, Areum Jo, Hye Hyeon Eum, Hong Kwan Kim, Kyungjong Lee, Jong Ho Cho, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Jung-Il Lee, Jung Won Choi, Dasom Jeong, Minsu Na, Huiram Kang, Jeong Yeon Kim, Jung Kyoon Choi, Hae-Ock Lee, Myung-Ju Ahn
Publikováno v:
eLife, Vol 13 (2024)
This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICIs). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, i
Externí odkaz:
https://doaj.org/article/a6cc1516727f4f3688947a807a310c49
Autor:
Young-gon Kim, Boram Lee, Changhee Ha, Cheonghwa Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Myung-Ju Ahn, Yoon-La Choi, Sehhoon Park, Jong-Won Kim
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionNumerous studies have suggested high concordance between tissue and circulating tumor DNA (ctDNA) comprehensive genomic profiling (CGP) tests but only few of them focused on fusions. In addition, atypical breakpoints occasionally detected
Externí odkaz:
https://doaj.org/article/dbc81487172d4e9cb14580b7c5c23ec4
Autor:
Junho Kang, Jun Hyeong Lee, Hongui Cha, Jinhyeon An, Joonha Kwon, Seongwoo Lee, Seongryong Kim, Mert Yakup Baykan, So Yeon Kim, Dohyeon An, Ah-Young Kwon, Hee Jung An, Se-Hoon Lee, Jung Kyoon Choi, Jong-Eun Park
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract The complexity of the tumor microenvironment poses significant challenges in cancer therapy. Here, to comprehensively investigate the tumor-normal ecosystems, we perform an integrative analysis of 4.9 million single-cell transcriptomes from
Externí odkaz:
https://doaj.org/article/105f3625e9d74191b0c8c5478582fe77
Autor:
Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, Sook Ryun Park, Shinkyo Yoon, Soohyeon Lee, Se-Hoon Lee, Tae Min Kim, Sae-Won Han, Hye Ryun Kim, Hongseok Yun, Sejoon Lee, Jihun Kim, Yoon-La Choi, Kui Son Choi, Heejung Chae, Hyewon Ryu, Gyeong-Won Lee, Dae Young Zang, Joong Bae Ahn
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Next-generation sequencing (NGS) has been introduced to many Korean institutions to support molecular diagnostics in cancer since 2017, when it became eligible for reimbursement by the National Health Insurance Service. However, t
Externí odkaz:
https://doaj.org/article/6e22c8fff5da40dc9f9e36884b464f4d
Autor:
Joo Kyung Park, Hyoung-oh Jeong, Hyemin Kim, Jin Ho Choi, Eun Mi Lee, Seunghoon Kim, Jinho Jang, David Whee-Young Choi, Se-Hoon Lee, Kyoung Mee Kim, Kee-Taek Jang, Kwang Hyuck Lee, Kyu Taek Lee, Min Woo Lee, Jong Kyun Lee, Semin Lee
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Background Intratumoral heterogeneity (ITH) and tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) play important roles in tumor evolution and patient outcomes. However, the precise characterization of diverse cell popul
Externí odkaz:
https://doaj.org/article/f7e91e3225c14813a26af18da590a5ed
Autor:
Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100700- (2024)
Introduction: Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consi
Externí odkaz:
https://doaj.org/article/0adb5b401a534eba8c323105cdaa5a38
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa